gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NYSE · EWHealthcareOrthopedic & Surgical Supplies

Edwards Lifesciences Corp (EW)

$99.37+4.39%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$99.67▲ 19.98% in range
Nov 3, 2025Low $75.87 · High $99.67Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Edwards Lifesciences closed at $99.37 on Nov 4, up 4.39% — matching its 52-week closing high. Volume of 7.9M shares was 1.85× its 20-day average (above normal).

Split-adjusted performance: +14.9% over one month, +19.4% over six months, +19.6% over one year.

In the quarter ended Jun 30, 2026, revenue was $1.74B, up 13.6% from a year earlier, with a net margin of 13.9%.

Short interest was 9.3M shares at the Oct 15 settlement, down 2.2% from the prior report (1.6% of float, 2.5 days to cover).

Market cap$57.28B576.4M shares
Revenue · quarter$1.74B+13.6% YoY
Diluted EPS$0.42−25.0% YoY
P/E · TTM57.0×P/S 8.8×
Net margin13.9%Gross 77.5%
Dividend yieldNone
52-week range75.87 – 99.370.0% from high
Volume7.9M1.85× 20-day avg
Volatility · 60d24.7%Annualised
Short % of float1.6%2.5 days to cover
Net cash$3.65BCash $4.25B
Next earnings—Not scheduled
Split-adjusted performance
1W +8.3%1M +14.9%3M +11.3%6M +19.4%YTD +16.6%1Y +19.6%3Y +59.3%5Y −14.4%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Orthopedic & Surgical Supplies

Percentile among 22 companies (100 = best)

6-month momentum75
Revenue growth53
Net margin95
Value (low P/E)14
Size95

Industry medians: 6-month return +1.5%, revenue growth +12.8%, net margin −2.8%, P/E 29.2×.

Short interest

Details →
Shares short9.3M−2.2% vs prior
Days to cover2.5Settled Oct 15
% of float1.6%
Short vol. 10d41.3%of daily volume

Closest peers by size in Orthopedic & Surgical Supplies

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
EWEdwards Lifesciences$99.37+4.39%+19.4%+13.6%13.9%57.0$57.28B
STESTERIS$247.91+7.16%+15.6%+7.3%13.4%30.0$24.17BCompare
ZBHZimmer Biomet Holdings$110.15+13.49%+33.0%+4.8%9.1%26.0$21.01BCompare
ISRGIntuitive Surgical$482.10+9.38%+6.7%+21.7%17.1%57.6$170.32BCompare
ALGNAlign Technology$164.90+8.79%−5.2%+4.3%10.3%28.3$11.71BCompare
MSAMine Safety Incorporated$177.60+2.03%+2.1%+14.5%10.9%22.6$6.85BCompare
ESTAEstablishment Labs Holdings$66.94+9.02%−10.2%+31.7%−17.4%—$1.99BCompare
ENOVEnovis$24.42+16.90%−1.7%+3.2%−0.2%—$1.41BCompare
CDRECadre Holdings$30.84−0.71%0.0%+31.8%5.5%36.6$1.32BCompare

News about Edwards Lifesciences

All news →
Edwards' Q3 Earnings on the Horizon: What's in the Cards?Zacks Investment Research · 5d ago▲ PositiveNCH Rooney Heart Institute Performs Nation’s First Tricuspid Valve Repair with PASCAL Precision System Following FDA ApprovalGlobeNewswire Inc. · 6d ago▲ PositiveTRiCares Announces Initiation of TRICURE US IDE Pivotal Study for Topaz Tricuspid Valve Replacement SystemGlobeNewswire Inc. · Jul 9, 2026NeutralEdwards Lifesciences Stands Out As US Agency Eyes Broader Access For Heart Valve DeviceBenzinga · Jun 16, 2026▲ PositiveEdwards Lifesciences Stock Surges On Heart Valve Devices GrowthBenzinga · Apr 24, 2026▲ Positive

Quick answers

What does Edwards Lifesciences do?
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies.
What is EW's market cap?
$57.28B, based on the Nov 4 close of $99.37.
What is EW's P/E ratio?
57.0× trailing-twelve-month earnings of $1B.
Does Edwards Lifesciences pay a dividend?
No regular cash dividend has been paid in the last year.
How much of EW is sold short?
9.3M shares, 1.6% of float, as of Oct 15, 2026.
What sector is EW in?
Healthcare, in the Orthopedic & Surgical Supplies industry.

About Edwards Lifesciences

Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.

HQ: Irvine, CA16,000 employeesListed Apr 3, 2000edwards.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology